Latest Close
$28.30
News
ROIV
Roivant Sciences Ltd. News
This news view pulls recent coverage and headlines tied to ROIV.
1y Change
$18.65 (+193.26%)
Market Cap
$20.25B
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
24/7 Wall St. • Apr 3, 2026
Read articleShould Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?
Simply Wall St. • Apr 3, 2026
Read articleImmunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
MarketBeat • Apr 2, 2026
Read articleRoivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint
MarketBeat • Apr 2, 2026
Read articleRoivant's Priovant Starts Phase 2b/3 Study of Brepocitinib in Inflammatory Scalp Disorder
MT Newswires • Apr 2, 2026
Read articlePriovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
GlobeNewswire • Apr 2, 2026
Read article